Updated on 2022/05/13

写真a

 
HANAJIRI Ryo
 
Organization
Nagoya University Hospital Hematology Assistant Professor
Graduate School
Graduate School of Medicine
Title
Assistant Professor

Degree 1

  1. 博士(医学) ( 2016.3   名古屋大学 ) 

Research Areas 1

  1. Life Science / Hematology and medical oncology

 

Papers 4

  1. Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells

    Adachi Yoshitaka, Sakai Toshiyasu, Terakura Seitaro, Shiina Takashi, Suzuki Shingo, Hamana Hiroshi, Kishi Hiroyuki, Sasazuki Takehiko, Arase Hisashi, Hanajiri Ryo, Goto Tatsunori, Nishida Tetsuya, Murata Makoto, Kiyoi Hitoshi

    INTERNATIONAL JOURNAL OF HEMATOLOGY   Vol. 115 ( 3 ) page: 371 - 381   2022.3

     More details

    Language:Japanese   Publisher:International Journal of Hematology  

    Genomic deletion of donor–patient-mismatched HLA alleles in leukemic cells is a major cause of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Mismatched HLA is frequently lost as an individual allele or a whole region in HLA-class I, however, it is downregulated in HLA-class II. We hypothesized that there might be a difference in T cell recognition capacity against epitopes associated with HLA-class I and HLA-class II and consequently such allogeneic immune pressure induced HLA alterations in leukemic cells. To investigate this, we conducted in vitro experiments with T cell receptor-transduced T (TCR-T) cells. The cytotoxic activity of NY-ESO-1-specific TCR-T cells exhibited similarly against K562 cells with low HLA-A*02:01 expression. However, we demonstrated that the cytokine production against low HLA-DPB1*05:01 expression line decreased gradually from the HLA expression level approximately 2-log lower than normal expressors. Using sort-purified leukemia cells before and after HSCT, we applied the next-generation sequencing, and revealed that there were several marked downregulations of HLA-class II alleles which demonstrated consistently low expression from pre-transplantation. The marked downregulation of HLA-class II may lead to decreased antigen recognition ability of antigen-specific T cells and may be one of immune evasion mechanism associated with HLA-class II downregulation.

    DOI: 10.1007/s12185-021-03273-w

    Web of Science

    Scopus

    PubMed

  2. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival

    Julamanee Jakrawadee, Terakura Seitaro, Umemura Koji, Adachi Yoshitaka, Miyao Kotaro, Okuno Shingo, Takagi Erina, Sakai Toshiyasu, Koyama Daisuke, Goto Tatsunori, Hanajiri Ryo, Hudecek Michael, Steinberger Peter, Leitner Judith, Nishida Tetsuya, Murata Makoto, Kiyoi Hitoshi

    MOLECULAR THERAPY   Vol. 29 ( 9 ) page: 2677 - 2690   2021.9

     More details

    Language:Japanese   Publisher:Molecular Therapy  

    Adoptively transferred CD19 chimeric antigen receptor (CAR) T cells have led to impressive clinical outcomes in B cell malignancies. Beyond induction of remission, the persistence of CAR-T cells is required to prevent relapse and provide long-term disease control. To improve CAR-T cell function and persistence, we developed a composite co-stimulatory domain of a B cell signaling moiety, CD79A/CD40, to induce a nuclear translocating signal, NF-κB, to synergize with other T cell signals and improve CAR-T cell function. CD79A/CD40 incorporating CD19CAR-T cells (CD19.79a.40z) exhibited higher NF-κB and p38 activity upon CD19 antigen exposure compared with the CD28 or 4-1BB incorporating CD19CAR-T cells (CD19.28z and CD19.BBz). Notably, we found that CD19.79a.40z CAR-T cells continued to suppress CD19+ target cells throughout the co-culture assay, whereas a tendency for tumor growth was observed with CD19.28z CAR-T cells. Moreover, CD19.79a.40z CAR-T cells exhibited robust T cell proliferation after culturing with CD19+ target cells, regardless of exogenous interleukin-2. In terms of in vivo efficiency, CD19.79a.40z demonstrated superior anti-tumor activity and in vivo CAR-T cell proliferation compared with CD19.28z and CD19.BBz CD19CAR-T cells in Raji-inoculated mice. Our data demonstrate that the CD79A/CD40 co-stimulatory domain endows CAR-T cells with enhanced proliferative capacity and improved anti-tumor efficacy in a murine model.

    DOI: 10.1016/j.ymthe.2021.04.038

    Web of Science

    Scopus

    PubMed

  3. Generation of Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy Reviewed

    Hanajiri R, Sani GM, Saunders D, Hanley PJ, Chopra A, Mallal SA, Sosnovtsev SV, Cohen JI, Green KY, Bollard CM, Keller MD

    J Infect Dis   Vol. 221 ( 4 ) page: 578 - 588   2020.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/infdis/jiz491

  4. Lupus anticoagulant-hypoprothrombinemia syndrome associated with follicular lymphoma Reviewed

    Koyama D, Hanajiri R, Kanematsu T, Ito R, Yamamoto S, Imoto N, Suzuki N, Kurahashi S, Sugiura I

    Rinsho Ketsueki   Vol. 61 ( 7 ) page: 745 - 749   2020

Presentations 2

  1. 造血幹細胞移植における HLA 抗体の臨床的意義 Invited

    葉名尻 良

    第 4 回 東海北陸 HLA 研究会  2021.7.24 

     More details

    Event date: 2021.7

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

  2. 高 IgE 症候群に併発した DLBCL の化学療法中に膿瘍を合併するもドレナージ術にて安全に治療可能であった 1 例

    葉名尻 良、川島 直実、牛島 洋子、島田 和之、石川 裕一、寺倉 精太郎、西田 徹也、村田 誠、清井 仁

    第10回日本血液学会東海地方会  2021.4.25 

     More details

    Event date: 2021.4

    Language:Japanese   Presentation type:Oral presentation (general)  

KAKENHI (Grants-in-Aid for Scientific Research) 1

  1. Adoptive immunotherapy for adult T-cell leukemia/lymphoma with ex vivo expanded multi-tumor associated antigen specific cytotoxic T-cells

    Grant number:20K17375  2020.4 - 2023.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )